HEPA - Hepion Pharmaceuticals Inc Stock Price, Fair Value and News

1.48USD-0.04 (-2.63%)Market Closed

Market Summary

USD1.48-0.04

Market Closed

-2.63%

HEPA Stock Price

View Fullscreen

HEPA RSI Chart

HEPA Valuation

Market Cap

8.1M

Price/Earnings (Trailing)

-0.17

EV/EBITDA

0.14

Price/Free Cashflow

-0.2

MarketCap/EBT

-0.16

HEPA Price/Sales (Trailing)

HEPA Profitability

Return on Equity

-671.99%

Return on Assets

-270.39%

Free Cashflow Yield

-505.16%

HEPA Fundamentals

HEPA Earnings

Earnings (TTM)

-48.9M

Earnings Growth (Yr)

-62.37%

Earnings Growth (Qtr)

-5.06%

Breaking Down HEPA Revenue

Last 7 days

8.0%

Last 30 days

-42.2%

How does HEPA drawdown profile look like?

HEPA Financial Health

Current Ratio

3.31

HEPA Investor Care

Shares Dilution (1Y)

13.81%

Diluted EPS (TTM)

-12.32

Tracking the Latest Insider Buys and Sells of Hepion Pharmaceuticals Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Nov 27, 2023	wijngaard peter	bought	7,625	3.05	2,500	-
Nov 24, 2023	wijngaard peter	bought	7,725	3.09	2,500	-
Sep 19, 2023	wijngaard peter	bought	5,640	5.64	1,000	-
Sep 18, 2023	foster robert t	bought	8,960	5.6	1,600	ceo and director
Sep 15, 2023	foster robert t	bought	8,640	5.4	1,600	ceo,cso and director
Sep 15, 2023	wijngaard peter	bought	11,201	5.60056	2,000	-
Feb 18, 2021	cavan john t	bought	20,000	2.00	10,000	chief financial officer
Feb 18, 2021	foster robert t	bought	40,000	2.00	20,000	ceo and director
Feb 16, 2021	wijngaard peter	bought	22,000	2.2	10,000	-
Dec 18, 2020	wijngaard peter	bought	38,200	1.91	20,000	-

Which funds bought or sold HEPA recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
Apr 29, 2024	BENJAMIN F. EDWARDS & COMPANY, INC.	unchanged	-	-	-	-%
Apr 25, 2024	Allworth Financial LP	unchanged	-	-1.00	3.00	-%
Apr 23, 2024	Global Retirement Partners, LLC	unchanged	-	-1.00	2.00	-%
Apr 12, 2024	HARBOR INVESTMENT ADVISORY, LLC	unchanged	-	-1.00	2.00	-%
Apr 12, 2024	AdvisorNet Financial, Inc	new	-	438	438	-%
Mar 22, 2024	PNC FINANCIAL SERVICES GROUP, INC.	unchanged	-	-5,038	9,328	-%
Mar 11, 2024	VANGUARD GROUP INC	reduced	-3.12	-306,388	519,517	-%
Feb 26, 2024	Virtu Financial LLC	new	-	41,000	41,000	-%
Feb 15, 2024	BARCLAYS PLC	unchanged	-	-	-	-%

Are Funds Buying or Selling HEPA?

Are funds buying HEPA calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own HEPA

No. of Funds

Unveiling Hepion Pharmaceuticals Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	armistice capital, llc	8.67%	418,000	SC 13G
Feb 14, 2022	altium capital management lp	0%	0	SC 13G/A
Jan 19, 2022	empery asset management, lp	0.44%	335,745	SC 13G/A
Jan 04, 2022	sabby management, llc	0.79%	603,812	SC 13G/A
Feb 24, 2021	altium capital management lp	5.9%	4,500,000	SC 13G
Feb 19, 2021	sabby management, llc	6.56%	5e+06	SC 13G
Feb 18, 2021	empery asset management, lp	5.25%	4e+06	SC 13G
Feb 16, 2021	cvi investments, inc.	-	420,000	SC 13G/A
Feb 10, 2021	vanguard group inc	5.96%	1,728,604	SC 13G
Feb 09, 2021	hudson bay capital management lp	0.92%	295,880	SC 13G/A

Recent SEC filings of Hepion Pharmaceuticals Inc

View All Filings

Date Filed	Form Type	Document
Apr 16, 2024	10-K	Annual Report
Apr 01, 2024	NT 10-K	NT 10-K
Mar 07, 2024	4	Insider Trading
Mar 06, 2024	8-K	Current Report
Mar 06, 2024	3	Insider Trading
Feb 21, 2024	4	Insider Trading
Feb 21, 2024	4	Insider Trading
Feb 21, 2024	4	Insider Trading
Feb 21, 2024	4	Insider Trading
Feb 20, 2024	8-K	Current Report

Peers (Alternatives to Hepion Pharmaceuticals Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	47.9B	6.8B	23.52%	-6.94%	-8.03	7	-64.45%	-224.75%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	19.3B	2.0B	0.99%	-25.83%	-58.02	9.62	75.20%	68.82%
BMRN	15.7B	2.5B	-4.94%	-13.58%	76.24	6.34	13.74%	186.89%
INCY	12.1B	3.8B	-2.80%	-18.78%	16.19	3.2	8.58%	129.81%
MID-CAP
APLS	5.7B	396.6M	-16.72%	-43.78%	-10.82	14.42	425.83%	18.94%
BBIO	5.2B	107.9M	-4.79%	106.15%	-9.53	48.09	54.84%	-28.31%
AXSM	3.5B	270.6M	1.74%	5.10%	-14.81	13.09	440.80%	-27.84%
ARWR	3.0B	240.7M	-7.74%	-39.00%	-10.2	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-7.55%	-20.97%	-45.79	3.86	40.45%	71.62%
SMALL-CAP
CPRX	1.7B	398.2M	-4.91%	-11.58%	24.31	4.36	85.90%	-14.05%
NVAX	687.2M	983.7M	8.15%	-35.14%	-1.26	0.7	-50.36%	17.16%
CRBP	408.0M	881.7K	0.99%	345.87%	-9.15	466.16	-77.61%	-5.33%
INO	282.8M	4.9M	-1.94%	21.49%	-2.09	58.11	-54.97%	51.71%
IBIO	6.9M	2.1M	-32.65%	86.79%	-0.25	2.14	-13.45%	66.37%

Hepion Pharmaceuticals Inc News

Latest updates

Hepion Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-27.6%	18,094	25,003	36,502	49,496	60,244	69,697	83,566	95,855	103,552	111,602	119,753	123,757	48,645	20,364	24,084	23,270	20,612	21,073	23,339	7,905	8,189
Current Assets	-17.8%	17,488	21,269	32,762	45,806	56,496	65,670	79,534	89,774	97,452	105,500	113,673	117,745	42,634	14,352	18,169	17,308	14,389	15,185	17,389	1,913	2,968
Cash Equivalents	-23.3%	14,786	19,284	30,522	42,993	51,189	59,145	71,708	79,223	91,349	98,731	110,091	115,449	40,727	13,711	17,562	16,048	13,923	14,864	17,149	1,683	2,832
Net PPE	-28.2%	29.00	41.00	61.00	64.00	82.00	83.00	106	131	153	200	200	200	108	45.00	53.00	48.00	57.00	58.00	65.00	66.00	32.00
Goodwill	-	-	-	-	-	-	-	-	1,871	1,871	1,871	1,871	1,871	1,871	1,871	1,871	1,871	1,871	1,871	1,871	1,871	1,871
Liabilities	22.3%	10,814	8,844	10,129	12,344	10,389	10,438	16,246	9,219	10,557	8,959	9,032	6,182	8,125	7,491	5,792	4,502	4,995	4,847	5,310	7,259	6,214
Current Liabilities	-17.4%	5,290	6,402	7,674	9,800	7,886	7,489	13,377	6,260	8,206	7,082	7,102	2,867	4,662	3,956	2,603	1,536	1,609	1,505	1,798	3,457	2,850
LT Debt, Current	-	-	-	-	-	-	-	-	-	-	-	-	177	-	-	-	-	-	330	790	1,070	1,440
Shareholder's Equity	-54.9%	7,281	16,159	26,373	37,152	49,856	59,259	67,320	86,636	92,995	102,644	110,725	117,580	40,520	12,873	17,723	18,199	15,617	15,976	17,779	395	1,725
Retained Earnings	-5.2%	-224,600	-213,567	-203,040	-188,961	-175,701	-168,900	-160,342	-140,430	-133,501	-127,094	-117,800	-110,162	-104,105	-99,149	-92,349	-87,409	-83,751	-81,288	-79,468	-78,447	-76,714
Additional Paid-In Capital	0.9%	230,291	228,125	227,806	224,489	223,951	226,535	225,989	225,354	224,788	228,023	226,834	226,022	142,911	110,310	108,924	104,459	97,651	95,798	95,773	77,327	76,653
Shares Outstanding	25.5%	4,819	3,838	3,838	3,811	3,811	3,811	3,811	3,811	3,811	3,415	3,811	2,608	1,601	-	-	-	-	-	-	-	-
Float	-	-	-	40,300	-	-	-	43,400	-	-	-	150,800	-	-	-	25,600	-	-	-	14,400	-	-

Cashflow (Last 12 Months)

(In )

Cashflow (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	19.4%	-9,012,896	-11,187,104	-12,500,000	-8,200,000	-4,836,330	-12,534,357	-7,500,003	-10,129,310	-7,382,267	-11,323,284	-5,169,682	-7,349,248	-4,525,408	-3,850,478	-3,111,354	-4,677,962	-2,440,181	-1,802,915	-1,263,536	-2,058,427	-5,092,490
Share Based Compensation	-52.9%	150,323	318,911	-1,059,676	1,930,753	231,943	616,835	162,508	1,541,450	847,520	1,468,525	1,394,899	957,871	985,826	990,677	394,611	8,246	14,379	17,129	17,192	17,506	-198,522
Cashflow From Investing	-113.5%	-348	2,582	-16,538	-	-16,336	-	2,266	-	1.00	-36,486	-11,815	-82,105	-76,546	-1.00	-11,436	2,194	-6,133	-2.00	-7,485	-37,849	-
Cashflow From Financing	-	4,494,950	-	-	-	-3,137,500	-	-	-2,000,000	-	-	-176,585	82,153,600	31,617,458	-	4,636,934	6,800,465	1,505,340	-482,197	16,737,475	946,453	-1,107,349

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

HEPA Income Statement

2023-12-31

Consolidated Statements of Operations - USD ($)	12 Months Ended
Consolidated Statements of Operations - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
Revenues	$ 0	$ 0
Costs and expenses:
Research and development	35,639,656	33,269,337
General and administrative	9,618,298	10,348,465
Impairment of in-process research and development and goodwill	3,190,000	1,870,924
Total operating expenses	48,447,954	45,488,726
Loss from operations	(48,447,954)	(45,488,726)
Other income (expense):
Interest expense	(9,465)	(10,164)
Change in fair value of contingent consideration and derivative financial instruments	(877,645)	414,992
Loss before income taxes	(49,335,064)	(45,083,898)
Income tax benefit (expense)	409,022	2,883,849
Net loss	(48,926,042)	(42,200,049)
Deemed dividend (see Note 4)	0	(3,137,500)
Net loss available to common stockholders, basic	(48,926,042)	(45,337,549)
Net loss attributable to common stockholders, diluted	$ (48,926,042)	$ (45,337,549)
Weighted average common shares outstanding:
Basic (in shares)	3,970,810	3,811,472
Diluted (in shares)	3,970,810	3,811,472
Net loss per common share: (see Note 11)
Basic (in dollars per share)	$ (12.32)	$ (11.90)
Diluted (in dollars per share)	$ (12.32)	$ (11.90)

HEPA Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash	$ 14,785,880	$ 51,189,088
Prepaid expenses	2,701,960	5,306,985
Total current assets	17,487,840	56,496,073
Property and equipment, net	29,487	81,620
Right-of-use assets	212,878	50,585
In-process research and development	0	3,190,000
Other assets	364,192	426,174
Total assets	18,094,397	60,244,452
Current liabilities:
Accounts payable	2,348,829	2,665,896
Accrued expenses	2,439,351	4,799,983
Operating lease liabilities, current	115,916	53,614
Short-term portion of contingent consideration	386,000	366,229
Total current liabilities	5,290,096	7,885,722
Contingent consideration, non-current	1,634,000	2,093,771
Deferred tax liability	0	409,022
Operating lease liabilities, non-current	93,104	0
Derivative financial instruments—warrants	3,796,390	0
Total liabilities	10,813,590	10,388,515
Commitments and contingencies (see Note 12)
Stockholders’ equity:
Common stock—$0.0001 par value per share; 120,000,000 shares authorized, 4,818,733 and 3,811,481 shares issued and outstanding at December 31, 2023 and 2022, respectively.	482	381
Additional paid-in capital	230,291,362	223,950,940
Accumulated other comprehensive loss	(78,779)	(90,168)
Accumulated deficit	(224,627,386)	(175,701,344)
Total stockholders equity	7,280,807	49,855,937
Total liabilities and stockholders’ equity	18,094,397	60,244,452
Series A
Stockholders’ equity:
Convertible preferred stock	855,808	855,808
Series C
Stockholders’ equity:
Convertible preferred stock	$ 839,320	$ 840,320

About Hepion Pharmaceuticals Inc

Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in phase 2 clinical development for the treatment of non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.

CEO	Dr. Robert T. Foster B.Sc., BSc (Pharm), Ph.D., Pharm.D.
WEBSITE	hepionpharma.com
INDUSTRY	Biotechnology
EMPLOYEES	25

Hepion Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Hepion Pharmaceuticals Inc? What does HEPA stand for in stocks?

HEPA is the stock ticker symbol of Hepion Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Hepion Pharmaceuticals Inc (HEPA)?

As of Fri May 03 2024, market cap of Hepion Pharmaceuticals Inc is 8.1 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of HEPA stock?

You can check HEPA's fair value in chart for subscribers.

What is the fair value of HEPA stock?

You can check HEPA's fair value in chart for subscribers. The fair value of Hepion Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Hepion Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for HEPA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Hepion Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether HEPA is over valued or under valued. Whether Hepion Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Hepion Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for HEPA.